Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study.

Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jørgensen CH, Lange T, Abildstrøm SZ, Schramm TK, Vaag A, Køber L, Torp-Pedersen C, Gislason GH.

Diabetologia. 2010 Dec;53(12):2546-53. doi: 10.1007/s00125-010-1906-6. Epub 2010 Sep 14.

PMID:
20838985
2.

Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes.

Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL.

J Clin Endocrinol Metab. 2013 Feb;98(2):668-77. doi: 10.1210/jc.2012-3042. Epub 2013 Jan 31.

3.
4.

The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.

Jil M, Rajnikant M, Richard D, Iskandar I.

Diab Vasc Dis Res. 2017 Jul;14(4):295-303. doi: 10.1177/1479164116687102. Epub 2017 Mar 23.

PMID:
28330386
5.

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.

PMID:
16186261
6.

Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

Johnson JA, Majumdar SR, Simpson SH, Toth EL.

Diabetes Care. 2002 Dec;25(12):2244-8.

PMID:
12453968
7.

Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.

Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C.

Diabetes Care. 2013 Nov;36(11):3746-53. doi: 10.2337/dc13-0027. Epub 2013 Oct 2.

8.

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

Bowker SL, Majumdar SR, Veugelers P, Johnson JA.

Diabetes Care. 2006 Feb;29(2):254-8.

PMID:
16443869
9.

Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study.

Mogensen UM, Andersson C, Fosbøl EL, Schramm TK, Vaag A, Scheller NM, Torp-Pedersen C, Gislason G, Køber L.

Diabetologia. 2015 Jan;58(1):50-8. doi: 10.1007/s00125-014-3372-z. Epub 2014 Sep 10.

PMID:
25205223
10.

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study.

Roumie CL, Min JY, D'Agostino McGowan L, Presley C, Grijalva CG, Hackstadt AJ, Hung AM, Greevy RA, Elasy T, Griffin MR.

J Am Heart Assoc. 2017 Apr 19;6(4). pii: e005379. doi: 10.1161/JAHA.116.005379.

11.

Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.

Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2177-2185. Epub 2016 Nov 8.

12.

Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.

Mamza J, Mehta R, Donnelly R, Idris I.

Ann Med. 2016;48(4):224-34. doi: 10.3109/07853890.2016.1157263. Epub 2016 Mar 16.

PMID:
26982210
13.

A comparison of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an expanded analysis from a retrospective cohort study.

Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, Yu S.

Curr Med Res Opin. 2014 Nov;30(11):2223-31. doi: 10.1185/03007995.2014.941054. Epub 2014 Jul 16.

PMID:
24983744
14.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Currie CJ, Poole CD, Gale EA.

Diabetologia. 2009 Sep;52(9):1766-77. doi: 10.1007/s00125-009-1440-6. Epub 2009 Jul 2.

PMID:
19572116
15.

Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.

Horsdal HT, Mehnert F, Rungby J, Johnsen SP.

J Stroke Cerebrovasc Dis. 2012 Nov;21(8):717-25. doi: 10.1016/j.jstrokecerebrovasdis.2011.03.007. Epub 2011 May 4.

PMID:
21536457
16.

Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: a nested case-control study.

Azoulay L, Schneider-Lindner V, Dell'aniello S, Schiffrin A, Suissa S.

Pharmacoepidemiol Drug Saf. 2010 Apr;19(4):335-42. doi: 10.1002/pds.1834.

PMID:
20052677
17.

Comparing the risks of hospitalized heart failure associated with glinide, sulfonylurea, and acarbose use in type 2 diabetes: A nationwide study.

Lee YC, Chang CH, Dong YH, Lin JW, Wu LC, Hwang JS, Chuang LM.

Int J Cardiol. 2017 Feb 1;228:1007-1014. doi: 10.1016/j.ijcard.2016.11.022. Epub 2016 Nov 10.

PMID:
27923207
18.

Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.

Bo S, Castiglione A, Ghigo E, Gentile L, Durazzo M, Cavallo-Perin P, Ciccone G.

Eur J Endocrinol. 2013 Jun 7;169(1):117-26. doi: 10.1530/EJE-13-0299. Print 2013 Jul.

19.

Secondary failure rates associated with metformin and sulfonylurea therapy for type 2 diabetes mellitus.

Eurich DT, Simpson SH, Majumdar SR, Johnson JA.

Pharmacotherapy. 2005 Jun;25(6):810-6.

PMID:
15927899
20.

Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.

Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM.

Am J Med Sci. 2008 Sep;336(3):241-7. doi: 10.1097/MAJ.0b013e31816250e6.

PMID:
18794619

Supplemental Content

Support Center